Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma

Figure 2 High mobility group-Box 3 during hepatocellular carcinoma progression[21,31-33,35]. Based on the data of basic or clinical studies, the progressive upregulation of high mobility group-Box 3 (HMGB3) at the mRNA or protein level occurred from the normal liver to chronic hepatitis to liver cirrhosis to hepatocellular carcinoma (HCC). An abnormal level of HMGB3 is helpful for monitoring hepatocyte malignant transformation and diagnosing or determining the prognosis of patients with HCC. In addition, interfering with HMGB3 transcription inhibited HCC cell proliferation in vitro or HCC xenograft growth in vivo. RAGE: Receptor for advanced glycation end products; TLR: Toll-like receptor; HCC: Hepatocellular carcinoma; HMGB3: High mobility group-Box 3.